Your session is about to expire
← Back to Search
Fat Tissue Injection vs Corticosteroid Injection for Shoulder Pain in Spinal Cord Injury (MFAT-SCI Trial)
MFAT-SCI Trial Summary
This trial is studying a new treatment for shoulder pain in people with chronic spinal cord injury. The new treatment is an injection of fat tissue, and the study will compare it to the standard-of-care corticosteroid injection.
MFAT-SCI Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowMFAT-SCI Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.MFAT-SCI Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am between 18 and 70 years old.I have had shoulder pain for over 6 months despite treatment.I have shoulder pain confirmed by an ultrasound to be due to rotator cuff issues.I have received MFAT treatment before.I have a chronic condition like diabetes or rheumatoid arthritis.I do not have any health conditions that could affect the study's results.My shoulder pain has been at least a 4 out of 10 in the past week.I use a wheelchair for most of my daily activities but can exercise.My shoulder pain has been at least a 4 out of 10 in the past week.I cannot undergo the procedure due to an infection, bleeding disorder, or because I'm on blood thinners.I have had a steroid injection in the last month.I have had a spinal cord injury between my neck and lower back over a year ago.
- Group 1: Corticosteroid
- Group 2: Micro-Fragmented Adipose Tissue
- Approved for 60 Other Conditions - This treatment demonstrated efficacy for 60 other conditions.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many individuals are being administered this medication in the current trial?
"The clinical trial is recruiting patients, as is evident from the information available on clinicaltrials.gov. This particular study was posted on 6/14/2019, with the most recent update taking place on 10/12/2022. They are currently looking for 24 participants at 1 location."
What is the most severe outcome that could result from Lipogems?
"There is some data supporting Lipogems's safety, but none yet to suggest that it is effective. It received a score of 2."
Would I be able to join this clinical trial?
"The requirements to sign up for this study are shoulder pain and being between 18-70 years old. Currently, the team is working on recruiting 24 individuals."
Are elderly citizens being recruited for this test?
"According to the eligibility requirements, patients taking part in this trial must be aged between 18 and 70. There are a total of 234 clinical trials available for minors and 1467 research studies involving seniors."
For what medical purposes is Lipogems typically employed?
"While ophthalmia, sympathetic is often the primary reason that Lipogems are used, this medication can also help patients suffering from branch retinal vein occlusion, and macular edema."
Will this experiment still be enrolling new participants?
"That is correct. The clinicaltrials.gov website says that the study is actively recruiting patients. This trial was first posted on June 14th, 2019 and was last updated October 12th, 2020. They are looking for a total of 24 volunteers at a single location."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger